Darunavir (Prezista®)

All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000605
English
Authors' recommendations: Darunavir (Prezista®) 800 mg once daily, co-administered with low dose ritonavir, is recommended as an option for use within NHS Wales for the treatment of HIV-1 infection in antiretroviral therapy-experienced adults with no darunavir resistance-associated mutations and who have plasma HIV-1 RNA <100,000 copies/mL and CD4+ cell count =100 cells × 106/l.
Details
Project Status: Completed
Year Published: 2012
URL for published report: http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&amp;id=195431&amp;pid=24773
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Wales, United Kingdom
MeSH Terms
  • Drug Therapy, Combination
  • Ritonavir
  • Antiretroviral Therapy, Highly Active
Contact
Organisation Name: All Wales Medicines Strategy Group
Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name: AWTTC@wales.nhs.uk
Contact Email: AWTTC@wales.nhs.uk
Copyright: AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.